Idiopathic and secondary osteoporosis in childhood;L'osteoporosi primitiva e secondaria in età pediatrica

Minerva Pediatrica

Volumn 57, Issue 5, 2005, Pages 203-211

  Rossi, F ^a   Perrotta, S ^a   Falcone, E ^a   Gimigliano, F ^a   Iodice, M ^a   Vetrella, S ^a   Iolascon, G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Childhood; Osteoporosis, diagnosis; Osteoporosis, therapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DEFEROXAMINE; GLUCOCORTICOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BETA THALASSEMIA; BONE DENSITY; BONE DISEASE; BONE FRAGILITY; BONE MARROW; BONE MARROW DISEASE; BONE MASS; CHRONIC DRUG ADMINISTRATION; CONNECTIVE TISSUE DISEASE; DELAYED PUBERTY; DISEASE PREDISPOSITION; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HEREDITY; HUMAN; IDIOPATHIC OSTEOPOROSIS; IRON OVERLOAD; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PUBERTY; REVIEW; THALASSEMIA; VERTEBRA FRACTURE;

ADOLESCENT; ADULT; AGE FACTORS; BONE DENSITY; CALCITONIN; CHILD; CHILD, PRESCHOOL; DENSITOMETRY, X-RAY; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THALASSEMIA;

EID: 28244486025     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Lindsay R, Cosman F. Primary osteoporosis. In: Coe FL, Flavus MJ editors. Disorders of bone and mineral metabolism. New York: Raven Press; 1992. p. 831-88.
2. Dempster DW. Bone remodeling. In: Coe FL, Flavus MJ editors. Disorders of bone and mineral metabolism. New York: Raven Press; 1992.
3. Frost HM. Dynamics of bone remodeling. In: Frost HM editor. Bone Biodynamics. Boston: Little, Brown and Co.; 1964. p. 315-33.
4. Passeri M. Aggiornamenti in tema di osteoporosi. Pavia: Edizioni Medico-Scientifiche; 2001.
5. Burkhardt P, Michel C. The peak of bone mass concept. Clin Rheumatol 1989;8:16-21.
6. Lelly PJ, Eisman IA, Sambrook PN. Interaction of genetic and environmental influences on bone peak bone density. Osteoporosis Int 1990;1:56-60.
7. Bonjour JP, Theinz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991;73:555-63.
8. Lu PW, Briody BJ, Ogle GD, Morley K, Humphries IR, Allen J et al. Bone mineral density of total body, spine and femoral neck in children and young adults: a cross sectional and longitudinal study. J Bone Miner Res 1994;9:1451-8.
9. Bianchi ML. Glucorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif Tissue Int 2002;70:384-90.
10. Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheum 1995;34:68-77.
11. Evans RA, Dunstan CR, Hills E. Bone metabolism in idiopathic juvenile osteoporosis: a case report. Calcif Tissue Int 1983;35:5-8.
12. Jowsey J, Johnson KA. Juvenile osteoporosis: bone findings in seven patients. J Pediatr 1972;81:511-7.
13. Smith R. Idiopathic osteoporosis in the young. J Bone Joint Surg Br 1980;62B:417-27.
14. Saggese G, Bertelloni S, Baroncelli GI, Perri G, Calderazzi A. Mineral metabolism and calcitriol therapy in idiopathic juvenile osteoporosis. Am J Dis Child 1991;145:457-6l.
15. Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calc Tissue Int 1984;36:245-52.
16. Canalis E. Mechanism of glucocorticoid actions in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrin Metab 1996;81:34-41.
17. Swolin D, Brantsing C, Matejka G, Ohlsson C. Cortisol decreases IGF-I mRNA levels in human osteoblast-like cells. J Endocrinol 1996;149:397-403.
18. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M. Use of bisphosphonates therapy for osteoporosis in childhood and adolescence. J Pediatr Child Health 2003;39:88-92.
19. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient. 4th ed. London: Academic Press; 2000.
20. Ruggiero L, De Sanctis V. Multicentre study on prevalence of fractures in transfusion dependent thalassemic patients. J Pediatr Endocrinol Metab 1998;11:773-8.
21. Lala R, Chiabotto P, Di Stefano M, Isaia GC, Garofano F, Piga A. Bone density and metabolism in thalassemia. J Pediatr Endocrinol Metab 1998;11:785-90.
22. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L et al. Osteoporosis in ,-thalassemia major patients: analysis of the genetic background. Br J Haematol 2000;111:461-6.
23. Ferrara M, Matarese SM, Francese M, Borrelli B, Coppola A, Coppola L et al. Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia. Br J Haematol 2002;117:436-40.
24. Eisman JA. Genetics of osteoporosis. Endocr Rev 1999;20:788-804.
25. Bielinski BK, Darbyshire PJ, Mathers L, Crabtree NJ, Kirk JMW, Stirling HF et al. Impact of disordered puberty on bone density in ,-thalassemia major. Br J Haematol 2003;120:353-8.
26. Filosa A, Di Maio S, Vocca S, Saviano A, Esposito G, Pagano L. Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis. Acta Paediatr 1997;86:342-6.
27. Anapliotou MLG, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassemia major: new therapeutic approaches. Clin Endocrinol 1995;42:279-87.
28. Kroger H, Kotaniemi A, Kroger L, Alhava E. Development of bone mass and bone density of the spine and femoral neck- a prospective study of 65 children and adolescents. Bone Miner 1993;23:171-82.
29. Sartorio A, Conte G, Conti A, Masala A, Alagna S, Rovasio P et al. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density deficient children with thalassemia major. J Endocrinol Invest 2000;23:356-61.
30. Pafumi C, Roccasalva L, Perticone G, Spanò G, Palombo MA, Di Gregorio F et al. Osteopenia in female ,-thalassemic patients. J Pediatr Endocrinol Metab 1998;11:989-91.
31. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A et al. High prevalence of low bone mass in thalassemia major. Br J Haematol 1998;103:911-5.
32. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR et al. Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996;155:368-72.
33. Orvieto R, Leichter I, Rachmilewitz EA, Margulies JY. Bone density, mineral content, and cortical index in patients with thalassemia major and their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcif Tissue Int 1992;50:397-9.
34. Wonke B. Bone disease in ,-thalassemia major. Br J Haematol 1998;103:897-901.
35. Garofalo F, Piga A, Lala R, Chiabotto S, Di Stefano M, Isaia GC. Bone metabolism in thalassemia. Ann N Y Acad Sci 1998;850:475-8.
36. Creep N, Anderson AL, Gallagher JC. Thalassemia minor: a risk factor for osteoporosis? Bone Miner 1992;16:63-72.
37. Kalef EJ, Challa A, Chaliasos N, Hatzikonstantinou I, Papaefstathiou I, Cholevas V et al. Bone minerals in beta-thalassemia minor. Bone 1995;16:651-5.
38. Singer S, Vichinsky EP. Bone disease in ,-thalassemia. Lancet 1999;354:881-2.
39. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A et al. High incidence of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab 1998;11:975-7.
40. Angastiniotis M, Pavlides N, Aristidou K, Kanakas A, Yerakaris M, Eracleous E et al. Bone pain in thalassemia: assessment of DEXA and MRI findings. J Pediatr Endocrinol Metab 1998;11:779-84.
41. Soliman AT, Banna NEL, Fattah MA, Elzalabani MM, Ansari BM. Bone mineral density in prepubertal children with ,-thalassemia: correlation with growth and hormonal data. Metabolism 1998;47:541-8.
42. Canatan D, Nejat A, Arcasoy A. Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol 1995;93:20-4.
43. Vichinsky EP. The morbidity of bone disease in thalassemia. Ann N Y Acad Sci 1998;850:344-8.
44. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A et al. Bone resorption is increased in young adults with thalassemia major. Br J Hematol 2001;112:36-41.
45. Pollak RD, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with ,-thalassemia major and intermedia. Br J Hematol 2000;111:902-7.
46. Dandona P, Menon RK, Houlder S, Thomas M, Hoffbrand AV, Flynn DM. Serum 1,25 dihydroxyvitamin D and osteocalcin concentrations in thalassemia major. Arch Dis Child 1987;62:474-7.
47. Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop Br 2003;12:77-87.
48. Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone 2003;32:268-74.
49. Adami S, Gatti D, Antoniazzi A, Viapiana O, Braga V. Intravenous neridronate in the treatment of patients with osteogenesis imperfecta. Sixth Workshop on bisphosphonates from laboratory to the patient. 2002, March 20-22, Davos, Switzerland.
50. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Ianoue G, Travers R: Cyclic aministration of pamidronate inchildren with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.